Summary
Global Markets Direct’s, ‘Type 2 Diabetes - Pipeline Review, H1 2016’, provides an overview of the Type 2 Diabetes pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Type 2 Diabetes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Type 2 Diabetes
- The report reviews pipeline therapeutics for Type 2 Diabetes by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Type 2 Diabetes therapeutics and enlists all their major and minor projects
- The report assesses Type 2 Diabetes therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Type 2 Diabetes
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic porfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Addex Therapeutics Ltd
Adocia
Advinus Therapeutics Ltd.
Aegis Therapeutics, LLC
AFFiRiS AG
Alchemia Limited
Alize Pharma SAS
AlphaMab Co., Ltd
Amarantus Bioscience Holdings, Inc.
Ambrx, Inc.
Amgen Inc.
Anchor Therapeutics, Inc.
AntriaBio, Inc.
Aphios Corporation
Araim Pharmaceuticals, Inc.
Arisaph Pharmaceuticals, Inc.
ArisGen SA
Array BioPharma Inc.
Artery Therapeutics, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
AUS Bio Limited
Avaxia Biologics, Inc.
Bayer AG
Beta-Cell NV
Betagenon AB
Biocon Limited
Biodel Inc.
Biogenomics Limited
BioLingus AG
BioRestorative Therapies, Inc.
BioTherapeutics Inc.
BioTime, Inc.
Biscayne Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Boston Therapeutics, Inc.
Braasch Biotech LLC
Bristol-Myers Squibb Company
C4X Discovery Holdings PLC
Cadila Pharmaceuticals Limited
Caldan Therapeutics Limited
Cardax Pharmaceuticals, Inc.
Carlina Technologies SAS
Carmot Therapeutics, Inc.
Catabasis Pharmaceuticals, Inc.
Celon Pharma Sp. z o.o.
Chipscreen Biosciences Ltd
Chong Kun Dang Pharmaceutical Corp.
CJ HealthCare Corp.
CohBar, Inc.
Connexios Life Sciences Pvt. Ltd.
Corium International, Inc.
CSL Limited
CureDM, Inc.
CymaBay Therapeutics, Inc.
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Dance Biopharm Inc.
Debiopharm International SA
Delpor, Inc.
Diabetica Limited
Diabetology (Products) Ltd
DiaMedica Inc.
Diasome Pharmaceuticals, Inc.
DiscoveryBiomed, Inc.
Eisai Co., Ltd.
Elcelyx Therapeutics, Inc.
Eli Lilly and Company
enGene, Inc
Enzo Biochem, Inc.
Epichem Pty Ltd
Esperion Therapeutics, Inc.
Eternygen GmbH
Euroscreen S.A.
Evotec AG
F. Hoffmann-La Roche Ltd.
FibroStatin SL
Flamel Technologies S.A.
Foresee Pharmaceuticals, LLC
Generex Biotechnology Corporation
Genfit SA
Genovate Biotechnology Co., LTD.
Gero Corp
Geropharm
GlaxoSmithKline Plc
Glide Pharmaceutical Technologies Limited
Glucox Biotech AB
GW Pharmaceuticals Plc
Hadasit Medical Research Services & Development Ltd
Halozyme Therapeutics, Inc.
HanAll Biopharma Co., Ltd.
Handok Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Heptares Therapeutics Limited
Hua Medicine Ltd.
Hyundai Pharmaceutical Co., Ltd.
Immuron Limited
Innopharmax Inc.
Intarcia Therapeutics, Inc.
Integral Molecular, Inc.
IntelliCell BioSciences Inc.
Intercept Pharmaceuticals, Inc.
Intrexon Corporation
Ionis Pharmaceuticals, Inc.
IPCA Laboratories Limited
Islet Sciences, Inc.
iTherX, Inc.
Japan Tobacco Inc.
Jeil Pharmaceutical Co., Ltd.
Jenrin Discovery, Inc.
JHL Biotech, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Johnson & Johnson
Kadimastem Ltd.
Kadmon Corporation, LLC
Kareus Therapeutics, SA
Kissei Pharmaceutical Co., Ltd.
Lexicon Pharmaceuticals, Inc.
LG Life Science LTD.
Ligand Pharmaceuticals, Inc.
Lonestar Heart, Inc.
Longevity Biotech, Inc
Magnus Life Science
Medesis Pharma S.A.
Medestea Research & Production S.p.A.
MedImmune, LLC
Mellitech SAS
Merck & Co., Inc.
Mesoblast Limited
Metabolic Solutions Development Company, LLC
Metabolys SAS
MI.TO. Technology S.r.L.
MicroBiome Therapeutics LLC
MidaSol Therapeutics LP
Mitsubishi Tanabe Pharma Corporation
Naia Limited
Neurimmune Holding AG
Neurocrine Biosciences, Inc.
NGM Biopharmaceuticals, Inc.
Nimbus Therapeutics, LLC
NOD Pharmaceuticals, Inc.
Nordic Bioscience A/S
Novartis AG
NovaTarg Therapeutics, Inc
Novo Nordisk A/S
Noxxon Pharma AG
Omeros Corporation
OPKO Health, Inc.
Oramed Pharmaceuticals, Inc.
Orbis Biosciences, Inc.
Panacea Biotec Limited
Paras Biopharmaceuticals Finland Oy
Peptron, Inc.
Pfizer Inc.
PharmaIN Corporation
PhaseBio Pharmaceuticals, Inc.
Pivot Pharmaceuticals Inc
Poxel SA
Progen Pharmaceuticals Limited
Prometheon Pharma, LLC
ProMetic Life Sciences Inc.
Prothena Corporation Plc
Purzer Pharmaceutical Co., Ltd.
Reata Pharmaceuticals, Inc.
Red Glead Discovery AB
RegenMedTX, LLC
reMYND NV
Rhizen Pharmaceuticals S.A.
Rhythm Pharmaceuticals, Inc.
Saniona AB
Sanofi
Sanwa Kagaku Kenkyusho Co., Ltd.
SATT Conectus Alsace SAS
SBI Pharmaceuticals Co., Ltd.
Seres Therapeutics, Inc.
Serodus ASA
Serometrix, LLC
Sevion Therapeutics, Inc.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Shanghai Pharmaceutical Co., Ltd.
Shantani Proteome Analytics Pvt. Ltd.
Shionogi & Co., Ltd.
Sihuan Pharmaceutical Holdings Group Ltd.
Sirona Biochem Corp
SJT Molecular Research, S.L.
SK Chemicals Co., Ltd.
Sprint Bioscience AB
Starpharma Holdings Limited
Stelic Institute & Co., Inc.
Strongbridge Biopharma plc
Sumitomo Dainippon Pharma Co., Ltd.
Taisho Pharmaceutical Holdings Co., Ltd.
Takeda Pharmaceutical Company Limited
Teijin Pharma Limited
Theracos, Inc.
Therapix Biosciences Ltd
Thermalin Diabetes, LLC
Thetis Pharmaceuticals LLC
Toray Industries, Inc.
Torrent Pharmaceuticals Limited
Transgene Biotek Limited
TWi Pharmaceuticals, Inc.
Uni-Bio Science Group Ltd.
Valeant Pharmaceuticals International, Inc.
Vicore Pharma AB
Viking Therapeutics, Inc.
Virobay Inc.
Vivus, Inc.
vTv Therapeutics LLC
Vybion, Inc.
XBiotech USA, Inc.
Xenetic Biosciences (UK) Limited
Xizang Haisco Pharmaceutical Group Co., Ltd.
XL-protein GmbH
XOMA Corporation
Yuhan Corporation
Yungjin Pharm. Co., Ltd.
Zafgen Inc.
Zealand Pharma A/S
Zensun (Shanghai) Sci & Tech Co., Ltd.
Zydus Cadila Healthcare Limited
'
Table of Contents
Table of Contents 2
Introduction 12
Type 2 Diabetes Overview 13
Therapeutics Development 14
Type 2 Diabetes - Therapeutics under Development by Companies 16
Type 2 Diabetes - Therapeutics under Investigation by Universities/Institutes 36
Type 2 Diabetes - Pipeline Products Glance 40
Type 2 Diabetes - Products under Development by Companies 44
Type 2 Diabetes - Products under Investigation by Universities/Institutes 79
Type 2 Diabetes - Companies Involved in Therapeutics Development 85
Type 2 Diabetes - Therapeutics Assessment 306
Drug Profiles 341
Type 2 Diabetes - Recent Pipeline Updates 1064
Type 2 Diabetes - Dormant Projects 1202
Type 2 Diabetes - Discontinued Products 1244
Type 2 Diabetes - Product Development Milestones 1263
Appendix 1268
List of Tables
Number of Products under Development for Type 2 Diabetes, H1 2016 74
Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H1 2016 75
Number of Products under Development by Companies, H1 2016 77
Number of Products under Development by Companies, H1 2016 (Contd..1) 78
Number of Products under Development by Companies, H1 2016 (Contd..2) 79
Number of Products under Development by Companies, H1 2016 (Contd..3) 80
Number of Products under Development by Companies, H1 2016 (Contd..4) 81
Number of Products under Development by Companies, H1 2016 (Contd..5) 82
Number of Products under Development by Companies, H1 2016 (Contd..6) 83
Number of Products under Development by Companies, H1 2016 (Contd..7) 84
Number of Products under Development by Companies, H1 2016 (Contd..8) 85
Number of Products under Development by Companies, H1 2016 (Contd..9) 86
Number of Products under Development by Companies, H1 2016 (Contd..10) 87
Number of Products under Development by Companies, H1 2016 (Contd..11) 88
Number of Products under Development by Companies, H1 2016 (Contd..12) 89
Number of Products under Development by Companies, H1 2016 (Contd..13) 90
Number of Products under Development by Companies, H1 2016 (Contd..14) 91
Number of Products under Development by Companies, H1 2016 (Contd..15) 92
Number of Products under Development by Companies, H1 2016 (Contd..16) 93
Number of Products under Development by Companies, H1 2016 (Contd..17) 94
Number of Products under Development by Companies, H1 2016 (Contd..18) 95
Number of Products under Investigation by Universities/Institutes, H1 2016 96
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 97
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 98
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 99
Comparative Analysis by Late Stage Development, H1 2016 100
Comparative Analysis by Clinical Stage Development, H1 2016 101
Comparative Analysis by Early Stage Development, H1 2016 102
Comparative Analysis by Unknown Stage Development, H1 2016 103
Products under Development by Companies, H1 2016 104
Products under Development by Companies, H1 2016 (Contd..1) 105
Products under Development by Companies, H1 2016 (Contd..2) 106
Products under Development by Companies, H1 2016 (Contd..3) 107
Products under Development by Companies, H1 2016 (Contd..4) 108
Products under Development by Companies, H1 2016 (Contd..5) 109
Products under Development by Companies, H1 2016 (Contd..6) 110
Products under Development by Companies, H1 2016 (Contd..7) 111
Products under Development by Companies, H1 2016 (Contd..8) 112
Products under Development by Companies, H1 2016 (Contd..9) 113
Products under Development by Companies, H1 2016 (Contd..10) 114
Products under Development by Companies, H1 2016 (Contd..11) 115
Products under Development by Companies, H1 2016 (Contd..12) 116
Products under Development by Companies, H1 2016 (Contd..13) 117
Products under Development by Companies, H1 2016 (Contd..14) 118
Products under Development by Companies, H1 2016 (Contd..15) 119
Products under Development by Companies, H1 2016 (Contd..16) 120
Products under Development by Companies, H1 2016 (Contd..17) 121
Products under Development by Companies, H1 2016 (Contd..18) 122
Products under Development by Companies, H1 2016 (Contd..19) 123
Products under Development by Companies, H1 2016 (Contd..20) 124
Products under Development by Companies, H1 2016 (Contd..21) 125
Products under Development by Companies, H1 2016 (Contd..22) 126
Products under Development by Companies, H1 2016 (Contd..23) 127
Products under Development by Companies, H1 2016 (Contd..24) 128
Products under Development by Companies, H1 2016 (Contd..25) 129
Products under Development by Companies, H1 2016 (Contd..26) 130
Products under Development by Companies, H1 2016 (Contd..27) 131
Products under Development by Companies, H1 2016 (Contd..28) 132
Products under Development by Companies, H1 2016 (Contd..29) 133
Products under Development by Companies, H1 2016 (Contd..30) 134
Products under Development by Companies, H1 2016 (Contd..31) 135
Products under Development by Companies, H1 2016 (Contd..32) 136
Products under Development by Companies, H1 2016 (Contd..33) 137
Products under Development by Companies, H1 2016 (Contd..34) 138
Products under Investigation by Universities/Institutes, H1 2016 139
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 140
Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 141
Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 142
Products under Investigation by Universities/Institutes, H1 2016 (Contd..4) 143
Products under Investigation by Universities/Institutes, H1 2016 (Contd..5) 144
Type 2 Diabetes - Pipeline by Addex Therapeutics Ltd, H1 2016 145
Type 2 Diabetes - Pipeline by Adocia, H1 2016 146
Type 2 Diabetes - Pipeline by Advinus Therapeutics Ltd., H1 2016 147
Type 2 Diabetes - Pipeline by Aegis Therapeutics, LLC, H1 2016 148
Type 2 Diabetes - Pipeline by AFFiRiS AG, H1 2016 149
Type 2 Diabetes - Pipeline by Alchemia Limited, H1 2016 150
Type 2 Diabetes - Pipeline by Alize Pharma SAS, H1 2016 151
Type 2 Diabetes - Pipeline by AlphaMab Co., Ltd, H1 2016 152
Type 2 Diabetes - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016 153
Type 2 Diabetes - Pipeline by Ambrx, Inc., H1 2016 154
Type 2 Diabetes - Pipeline by Amgen Inc., H1 2016 155
Type 2 Diabetes - Pipeline by Anchor Therapeutics, Inc., H1 2016 156
Type 2 Diabetes - Pipeline by AntriaBio, Inc., H1 2016 157
Type 2 Diabetes - Pipeline by Aphios Corporation, H1 2016 158
Type 2 Diabetes - Pipeline by Araim Pharmaceuticals, Inc., H1 2016 159
Type 2 Diabetes - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016 160
Type 2 Diabetes - Pipeline by ArisGen SA, H1 2016 161
Type 2 Diabetes - Pipeline by Array BioPharma Inc., H1 2016 162
Type 2 Diabetes - Pipeline by Artery Therapeutics, Inc., H1 2016 163
Type 2 Diabetes - Pipeline by Astellas Pharma Inc., H1 2016 164
Type 2 Diabetes - Pipeline by AstraZeneca Plc, H1 2016 165
Type 2 Diabetes - Pipeline by AUS Bio Limited, H1 2016 166
Type 2 Diabetes - Pipeline by Avaxia Biologics, Inc., H1 2016 167
Type 2 Diabetes - Pipeline by Bayer AG, H1 2016 168
Type 2 Diabetes - Pipeline by Beta-Cell NV, H1 2016 169
Type 2 Diabetes - Pipeline by Betagenon AB, H1 2016 170
Type 2 Diabetes - Pipeline by Biocon Limited, H1 2016 171
Type 2 Diabetes - Pipeline by Biodel Inc., H1 2016 172
Type 2 Diabetes - Pipeline by Biogenomics Limited, H1 2016 173
Type 2 Diabetes - Pipeline by BioLingus AG, H1 2016 174
Type 2 Diabetes - Pipeline by BioRestorative Therapies, Inc., H1 2016 175
Type 2 Diabetes - Pipeline by BioTherapeutics Inc., H1 2016 176
Type 2 Diabetes - Pipeline by BioTime, Inc., H1 2016 177
Type 2 Diabetes - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2016 178
Type 2 Diabetes - Pipeline by Boehringer Ingelheim GmbH, H1 2016 179
Type 2 Diabetes - Pipeline by Boston Therapeutics, Inc., H1 2016 180
Type 2 Diabetes - Pipeline by Braasch Biotech LLC, H1 2016 181
Type 2 Diabetes - Pipeline by Bristol-Myers Squibb Company, H1 2016 182
Type 2 Diabetes - Pipeline by C4X Discovery Holdings PLC, H1 2016 183
Type 2 Diabetes - Pipeline by Cadila Pharmaceuticals Limited, H1 2016 184
Type 2 Diabetes - Pipeline by Caldan Therapeutics Limited, H1 2016 185
Type 2 Diabetes - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016 186
Type 2 Diabetes - Pipeline by Carlina Technologies SAS, H1 2016 187
Type 2 Diabetes - Pipeline by Carmot Therapeutics, Inc., H1 2016 188
Type 2 Diabetes - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2016 189
Type 2 Diabetes - Pipeline by Celon Pharma Sp. z o.o., H1 2016 190
Type 2 Diabetes - Pipeline by Chipscreen Biosciences Ltd, H1 2016 191
Type 2 Diabetes - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 192
Type 2 Diabetes - Pipeline by CJ HealthCare Corp., H1 2016 193
Type 2 Diabetes - Pipeline by CohBar, Inc., H1 2016 194
Type 2 Diabetes - Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2016 195
Type 2 Diabetes - Pipeline by Corium International, Inc., H1 2016 196
Type 2 Diabetes - Pipeline by CSL Limited, H1 2016 197
Type 2 Diabetes - Pipeline by CureDM, Inc., H1 2016 198
Type 2 Diabetes - Pipeline by CymaBay Therapeutics, Inc., H1 2016 199
Type 2 Diabetes - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 200
Type 2 Diabetes - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 201
Type 2 Diabetes - Pipeline by Dance Biopharm Inc., H1 2016 202
Type 2 Diabetes - Pipeline by Debiopharm International SA , H1 2016 203
Type 2 Diabetes - Pipeline by Delpor, Inc., H1 2016 204
Type 2 Diabetes - Pipeline by Diabetica Limited, H1 2016 205
Type 2 Diabetes - Pipeline by Diabetology (Products) Ltd, H1 2016 206
Type 2 Diabetes - Pipeline by DiaMedica Inc., H1 2016 207
Type 2 Diabetes - Pipeline by Diasome Pharmaceuticals, Inc., H1 2016 208
Type 2 Diabetes - Pipeline by DiscoveryBiomed, Inc., H1 2016 209
Type 2 Diabetes - Pipeline by Eisai Co., Ltd., H1 2016 210
Type 2 Diabetes - Pipeline by Elcelyx Therapeutics, Inc., H1 2016 211
Type 2 Diabetes - Pipeline by Eli Lilly and Company, H1 2016 212
Type 2 Diabetes - Pipeline by enGene, Inc, H1 2016 213
Type 2 Diabetes - Pipeline by Enzo Biochem, Inc., H1 2016 214
Type 2 Diabetes - Pipeline by Epichem Pty Ltd, H1 2016 215
Type 2 Diabetes - Pipeline by Esperion Therapeutics, Inc., H1 2016 216
Type 2 Diabetes - Pipeline by Eternygen GmbH, H1 2016 217
Type 2 Diabetes - Pipeline by Euroscreen S.A., H1 2016 218
Type 2 Diabetes - Pipeline by Evotec AG, H1 2016 219
Type 2 Diabetes - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 220
Type 2 Diabetes - Pipeline by FibroStatin SL, H1 2016 221
Type 2 Diabetes - Pipeline by Flamel Technologies S.A., H1 2016 222
Type 2 Diabetes - Pipeline by Foresee Pharmaceuticals, LLC, H1 2016 223
Type 2 Diabetes - Pipeline by Generex Biotechnology Corporation, H1 2016 224
Type 2 Diabetes - Pipeline by Genfit SA, H1 2016 225
Type 2 Diabetes - Pipeline by Genovate Biotechnology Co., LTD., H1 2016 226
Type 2 Diabetes - Pipeline by Gero Corp, H1 2016 227
Type 2 Diabetes - Pipeline by Geropharm, H1 2016 228
Type 2 Diabetes - Pipeline by GlaxoSmithKline Plc, H1 2016 229
Type 2 Diabetes - Pipeline by Glide Pharmaceutical Technologies Limited, H1 2016 230
Type 2 Diabetes - Pipeline by Glucox Biotech AB, H1 2016 231
Type 2 Diabetes - Pipeline by GW Pharmaceuticals Plc, H1 2016 232
Type 2 Diabetes - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2016 233
Type 2 Diabetes - Pipeline by Halozyme Therapeutics, Inc., H1 2016 234
Type 2 Diabetes - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 235
Type 2 Diabetes - Pipeline by Handok Inc., H1 2016 236
Type 2 Diabetes - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 237
Type 2 Diabetes - Pipeline by Heptares Therapeutics Limited, H1 2016 238
Type 2 Diabetes - Pipeline by Hua Medicine Ltd., H1 2016 239
Type 2 Diabetes - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016 240
Type 2 Diabetes - Pipeline by Immuron Limited, H1 2016 241
Type 2 Diabetes - Pipeline by Innopharmax Inc., H1 2016 242
Type 2 Diabetes - Pipeline by Intarcia Therapeutics, Inc., H1 2016 243
Type 2 Diabetes - Pipeline by Integral Molecular, Inc., H1 2016 244
Type 2 Diabetes - Pipeline by IntelliCell BioSciences Inc., H1 2016 245
Type 2 Diabetes - Pipeline by Intercept Pharmaceuticals, Inc., H1 2016 246
Type 2 Diabetes - Pipeline by Intrexon Corporation, H1 2016 247
Type 2 Diabetes - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 248
Type 2 Diabetes - Pipeline by IPCA Laboratories Limited, H1 2016 249
Type 2 Diabetes - Pipeline by Islet Sciences, Inc., H1 2016 250
Type 2 Diabetes - Pipeline by iTherX, Inc., H1 2016 251
Type 2 Diabetes - Pipeline by Japan Tobacco Inc., H1 2016 252
Type 2 Diabetes - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016 253
Type 2 Diabetes - Pipeline by Jenrin Discovery, Inc., H1 2016 254
Type 2 Diabetes - Pipeline by JHL Biotech, Inc., H1 2016 255
Type 2 Diabetes - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016 256
Type 2 Diabetes - Pipeline by Johnson & Johnson, H1 2016 257
Type 2 Diabetes - Pipeline by Kadimastem Ltd., H1 2016 258
Type 2 Diabetes - Pipeline by Kadmon Corporation, LLC, H1 2016 259
Type 2 Diabetes - Pipeline by Kareus Therapeutics, SA, H1 2016 260
Type 2 Diabetes - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016 261
Type 2 Diabetes - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2016 262
Type 2 Diabetes - Pipeline by LG Life Science LTD., H1 2016 263
Type 2 Diabetes - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 264
Type 2 Diabetes - Pipeline by Lonestar Heart, Inc., H1 2016 265
Type 2 Diabetes - Pipeline by Longevity Biotech, Inc, H1 2016 266
Type 2 Diabetes - Pipeline by Magnus Life Science, H1 2016 267
Type 2 Diabetes - Pipeline by Medesis Pharma S.A., H1 2016 268
Type 2 Diabetes - Pipeline by Medestea Research & Production S.p.A., H1 2016 269
Type 2 Diabetes - Pipeline by MedImmune, LLC, H1 2016 270
Type 2 Diabetes - Pipeline by Mellitech SAS, H1 2016 271
Type 2 Diabetes - Pipeline by Merck & Co., Inc., H1 2016 272
Type 2 Diabetes - Pipeline by Mesoblast Limited, H1 2016 273
Type 2 Diabetes - Pipeline by Metabolic Solutions Development Company, LLC, H1 2016 274
Type 2 Diabetes - Pipeline by Metabolys SAS, H1 2016 275
Type 2 Diabetes - Pipeline by MI.TO. Technology S.r.L., H1 2016 276
Type 2 Diabetes - Pipeline by MicroBiome Therapeutics LLC, H1 2016 277
Type 2 Diabetes - Pipeline by MidaSol Therapeutics LP, H1 2016 278
Type 2 Diabetes - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 279
Type 2 Diabetes - Pipeline by Naia Limited, H1 2016 280
Type 2 Diabetes - Pipeline by Neurimmune Holding AG, H1 2016 281
Type 2 Diabetes - Pipeline by Neurocrine Biosciences, Inc., H1 2016 282
Type 2 Diabetes - Pipeline by NGM Biopharmaceuticals, Inc., H1 2016 283
Type 2 Diabetes - Pipeline by Nimbus Therapeutics, LLC, H1 2016 284
Type 2 Diabetes - Pipeline by NOD Pharmaceuticals, Inc., H1 2016 285
Type 2 Diabetes - Pipeline by Nordic Bioscience A/S, H1 2016 286
Type 2 Diabetes - Pipeline by Novartis AG, H1 2016 287
Type 2 Diabetes - Pipeline by NovaTarg Therapeutics, Inc, H1 2016 288
Type 2 Diabetes - Pipeline by Novo Nordisk A/S, H1 2016 289
Type 2 Diabetes - Pipeline by Noxxon Pharma AG, H1 2016 290
Type 2 Diabetes - Pipeline by Omeros Corporation, H1 2016 291
Type 2 Diabetes - Pipeline by OPKO Health, Inc., H1 2016 292
Type 2 Diabetes - Pipeline by Oramed Pharmaceuticals, Inc., H1 2016 293
Type 2 Diabetes - Pipeline by Orbis Biosciences, Inc., H1 2016 294
Type 2 Diabetes - Pipeline by Panacea Biotec Limited, H1 2016 295
Type 2 Diabetes - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2016 296
Type 2 Diabetes - Pipeline by Peptron, Inc., H1 2016 297
Type 2 Diabetes - Pipeline by Pfizer Inc., H1 2016 298
Type 2 Diabetes - Pipeline by PharmaIN Corporation, H1 2016 299
Type 2 Diabetes - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016 300
Type 2 Diabetes - Pipeline by Pivot Pharmaceuticals Inc, H1 2016 301
Type 2 Diabetes - Pipeline by Poxel SA, H1 2016 302
Type 2 Diabetes - Pipeline by Progen Pharmaceuticals Limited, H1 2016 303
Type 2 Diabetes - Pipeline by Prometheon Pharma, LLC, H1 2016 304
Type 2 Diabetes - Pipeline by ProMetic Life Sciences Inc., H1 2016 305
Type 2 Diabetes - Pipeline by Prothena Corporation Plc, H1 2016 306
Type 2 Diabetes - Pipeline by Purzer Pharmaceutical Co., Ltd., H1 2016 307
Type 2 Diabetes - Pipeline by Reata Pharmaceuticals, Inc., H1 2016 308
Type 2 Diabetes - Pipeline by Red Glead Discovery AB, H1 2016 309
Type 2 Diabetes - Pipeline by RegenMedTX, LLC, H1 2016 310
Type 2 Diabetes - Pipeline by reMYND NV, H1 2016 311
Type 2 Diabetes - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016 312
Type 2 Diabetes - Pipeline by Rhythm Pharmaceuticals, Inc., H1 2016 313
Type 2 Diabetes - Pipeline by Saniona AB, H1 2016 314
Type 2 Diabetes - Pipeline by Sanofi, H1 2016 315
Type 2 Diabetes - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2016 316
Type 2 Diabetes - Pipeline by SATT Conectus Alsace SAS, H1 2016 317
Type 2 Diabetes - Pipeline by SBI Pharmaceuticals Co., Ltd., H1 2016 318
Type 2 Diabetes - Pipeline by Seres Therapeutics, Inc., H1 2016 319
Type 2 Diabetes - Pipeline by Serodus ASA, H1 2016 320
Type 2 Diabetes - Pipeline by Serometrix, LLC, H1 2016 321
Type 2 Diabetes - Pipeline by Sevion Therapeutics, Inc., H1 2016 322
Type 2 Diabetes - Pipeline by Shanghai Fosun Pharmaceutical (Group) Co., Ltd., H1 2016 323
Type 2 Diabetes - Pipeline by Shanghai Pharmaceutical Co., Ltd., H1 2016 324
Type 2 Diabetes - Pipeline by Shantani Proteome Analytics Pvt. Ltd., H1 2016 325
Type 2 Diabetes - Pipeline by Shionogi & Co., Ltd., H1 2016 326
Type 2 Diabetes - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 327Type 2 Diabetes - Pipeline by Sirona Biochem Corp, H1 2016 328
Type 2 Diabetes - Pipeline by SJT Molecular Research, S.L. , H1 2016 329
Type 2 Diabetes - Pipeline by SK Chemicals Co., Ltd., H1 2016 330
Type 2 Diabetes - Pipeline by Sprint Bioscience AB, H1 2016 331
Type 2 Diabetes - Pipeline by Starpharma Holdings Limited, H1 2016 332
Type 2 Diabetes - Pipeline by Stelic Institute & Co., Inc., H1 2016 333
Type 2 Diabetes - Pipeline by Strongbridge Biopharma plc , H1 2016 334
Type 2 Diabetes - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 335
Type 2 Diabetes - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H1 2016 336
Type 2 Diabetes - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 337
Type 2 Diabetes - Pipeline by Teijin Pharma Limited, H1 2016 338
Type 2 Diabetes - Pipeline by Theracos, Inc., H1 2016 339
Type 2 Diabetes - Pipeline by Therapix Biosciences Ltd, H1 2016 340
Type 2 Diabetes - Pipeline by Thermalin Diabetes, LLC, H1 2016 341
Type 2 Diabetes - Pipeline by Thetis Pharmaceuticals LLC, H1 2016 342
Type 2 Diabetes - Pipeline by Toray Industries, Inc., H1 2016 343
Type 2 Diabetes - Pipeline by Torrent Pharmaceuticals Limited, H1 2016 344
Type 2 Diabetes - Pipeline by Transgene Biotek Limited, H1 2016 345
Type 2 Diabetes - Pipeline by TWi Pharmaceuticals, Inc., H1 2016 346
Type 2 Diabetes - Pipeline by Uni-Bio Science Group Ltd., H1 2016 347
Type 2 Diabetes - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 348
Type 2 Diabetes - Pipeline by Vicore Pharma AB, H1 2016 349
Type 2 Diabetes - Pipeline by Viking Therapeutics, Inc., H1 2016 350
Type 2 Diabetes - Pipeline by Virobay Inc., H1 2016 351
Type 2 Diabetes - Pipeline by Vivus, Inc., H1 2016 352
Type 2 Diabetes - Pipeline by vTv Therapeutics LLC, H1 2016 353
Type 2 Diabetes - Pipeline by Vybion, Inc., H1 2016 354
Type 2 Diabetes - Pipeline by XBiotech USA, Inc., H1 2016 355
Type 2 Diabetes - Pipeline by Xenetic Biosciences (UK) Limited, H1 2016 356
Type 2 Diabetes - Pipeline by Xizang Haisco Pharmaceutical Group Co., Ltd., H1 2016 357
Type 2 Diabetes - Pipeline by XL-protein GmbH, H1 2016 358
Type 2 Diabetes - Pipeline by XOMA Corporation, H1 2016 359
Type 2 Diabetes - Pipeline by Yuhan Corporation, H1 2016 360
Type 2 Diabetes - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016 361
Type 2 Diabetes - Pipeline by Zafgen Inc., H1 2016 362
Type 2 Diabetes - Pipeline by Zealand Pharma A/S, H1 2016 363
Type 2 Diabetes - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2016 364
Type 2 Diabetes - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 365
Assessment by Monotherapy Products, H1 2016 366
Assessment by Combination Products, H1 2016 367
Number of Products by Stage and Target, H1 2016 369
Number of Products by Stage and Mechanism of Action, H1 2016 385
Number of Products by Stage and Route of Administration, H1 2016 398
Number of Products by Stage and Molecule Type, H1 2016 400
Type 2 Diabetes Therapeutics - Recent Pipeline Updates, H1 2016 1124
Type 2 Diabetes - Dormant Projects, H1 2016 1262
Type 2 Diabetes - Dormant Projects (Contd..1), H1 2016 1263
Type 2 Diabetes - Dormant Projects (Contd..2), H1 2016 1264
Type 2 Diabetes - Dormant Projects (Contd..3), H1 2016 1265
Type 2 Diabetes - Dormant Projects (Contd..4), H1 2016 1266
Type 2 Diabetes - Dormant Projects (Contd..5), H1 2016 1267
Type 2 Diabetes - Dormant Projects (Contd..6), H1 2016 1268
Type 2 Diabetes - Dormant Projects (Contd..7), H1 2016 1269
Type 2 Diabetes - Dormant Projects (Contd..8), H1 2016 1270
Type 2 Diabetes - Dormant Projects (Contd..9), H1 2016 1271
Type 2 Diabetes - Dormant Projects (Contd..10), H1 2016 1272
Type 2 Diabetes - Dormant Projects (Contd..11), H1 2016 1273
Type 2 Diabetes - Dormant Projects (Contd..12), H1 2016 1274
Type 2 Diabetes - Dormant Projects (Contd..13), H1 2016 1275
Type 2 Diabetes - Dormant Projects (Contd..14), H1 2016 1276
Type 2 Diabetes - Dormant Projects (Contd..15), H1 2016 1277
Type 2 Diabetes - Dormant Projects (Contd..16), H1 2016 1278
Type 2 Diabetes - Dormant Projects (Contd..17), H1 2016 1279
Type 2 Diabetes - Dormant Projects (Contd..18), H1 2016 1280
Type 2 Diabetes - Dormant Projects (Contd..19), H1 2016 1281
Type 2 Diabetes - Dormant Projects (Contd..20), H1 2016 1282
Type 2 Diabetes - Dormant Projects (Contd..21), H1 2016 1283
Type 2 Diabetes - Dormant Projects (Contd..22), H1 2016 1284
Type 2 Diabetes - Dormant Projects (Contd..23), H1 2016 1285
Type 2 Diabetes - Dormant Projects (Contd..24), H1 2016 1286
Type 2 Diabetes - Dormant Projects (Contd..25), H1 2016 1287
Type 2 Diabetes - Dormant Projects (Contd..26), H1 2016 1288
Type 2 Diabetes - Dormant Projects (Contd..27), H1 2016 1289
Type 2 Diabetes - Dormant Projects (Contd..28), H1 2016 1290
Type 2 Diabetes - Dormant Projects (Contd..29), H1 2016 1291
Type 2 Diabetes - Dormant Projects (Contd..30), H1 2016 1292
Type 2 Diabetes - Dormant Projects (Contd..31), H1 2016 1293
Type 2 Diabetes - Dormant Projects (Contd..32), H1 2016 1294
Type 2 Diabetes - Dormant Projects (Contd..33), H1 2016 1295
Type 2 Diabetes - Dormant Projects (Contd..34), H1 2016 1296
Type 2 Diabetes - Dormant Projects (Contd..35), H1 2016 1297
Type 2 Diabetes - Dormant Projects (Contd..36), H1 2016 1298
Type 2 Diabetes - Dormant Projects (Contd..37), H1 2016 1299
Type 2 Diabetes - Dormant Projects (Contd..38), H1 2016 1300
Type 2 Diabetes - Dormant Projects (Contd..39), H1 2016 1301
Type 2 Diabetes - Dormant Projects (Contd..40), H1 2016 1302
Type 2 Diabetes - Dormant Projects (Contd..41), H1 2016 1303
Type 2 Diabetes - Discontinued Products, H1 2016 1304
Type 2 Diabetes - Discontinued Products (Contd..1), H1 2016 1305
Type 2 Diabetes - Discontinued Products (Contd..2), H1 2016 1306
Type 2 Diabetes - Discontinued Products (Contd..3), H1 2016 1307
Type 2 Diabetes - Discontinued Products (Contd..4), H1 2016 1308
Type 2 Diabetes - Discontinued Products (Contd..5), H1 2016 1309
Type 2 Diabetes - Discontinued Products (Contd..6), H1 2016 1310
Type 2 Diabetes - Discontinued Products (Contd..7), H1 2016 1311
Type 2 Diabetes - Discontinued Products (Contd..8), H1 2016 1312
Type 2 Diabetes - Discontinued Products (Contd..9), H1 2016 1313
Type 2 Diabetes - Discontinued Products (Contd..10), H1 2016 1314
Type 2 Diabetes - Discontinued Products (Contd..11), H1 2016 1315
Type 2 Diabetes - Discontinued Products (Contd..12), H1 2016 1316
Type 2 Diabetes - Discontinued Products (Contd..13), H1 2016 1317
Type 2 Diabetes - Discontinued Products (Contd..14), H1 2016 1318
Type 2 Diabetes - Discontinued Products (Contd..15), H1 2016 1319
Type 2 Diabetes - Discontinued Products (Contd..16), H1 2016 1320
Type 2 Diabetes - Discontinued Products (Contd..17), H1 2016 1321
Type 2 Diabetes - Discontinued Products (Contd..18), H1 2016 1322
List of Figures
Number of Products under Development for Type 2 Diabetes, H1 2016 74
Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H1 2016 75
Number of Products under Development by Companies, H1 2016 76
Number of Products under Investigation by Universities/Institutes, H1 2016 96
Comparative Analysis by Late Stage Development, H1 2016 100
Comparative Analysis by Clinical Stage Development, H1 2016 101
Comparative Analysis by Early Stage Products, H1 2016 102
Assessment by Monotherapy Products, H1 2016 366
Assessment by Combination Products, H1 2016 367
Number of Products by Top 10 Targets, H1 2016 368
Number of Products by Stage and Top 10 Targets, H1 2016 368
Number of Products by Top 10 Mechanism of Actions, H1 2016 384
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 384
Number of Products by Top 10 Routes of Administration, H1 2016 397
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 397
Number of Products by Top 10 Molecule Types, H1 2016 399
Number of Products by Stage and Top 10 Molecule Types, H1 2016 399
